• Evolus to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

    Source: Nasdaq GlobeNewswire / 19 Feb 2021 16:05:00   America/New_York

    NEWPORT BEACH, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference.

     Event: 10th Annual SVB Leerink Global Healthcare Conference
     Format: Fireside Chat & 1x1 Meetings
     Date: Wednesday, February 24, 2021
     Time: 1:00pm – 1:30pm ET
     Location: Evolus Live Fireside Chat

    An audio webcast of Evolus’ fireside chat will be available on the investor relations section of Evolus’ website at investors.evolus.com. Replays of the webcasts will be available for 90 days after the date of the presentation.

    About Evolus, Inc.

    Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.

    Jeuveau® is a registered trademark of Evolus, Inc.

    Hi-Pure is a trademark of Daewoong Pharmaceutical Co, Ltd.

    Evolus, Inc. Contacts:

    Investor Contact:
    Ashwin Agarwal, Evolus, Inc.
    Vice President, Finance, Investor Relations & Treasury
    Tel: +1-949-284-4559
    Email: IR@Evolus.com

    Media Contact:
    Crystal Muilenburg, Evolus, Inc.
    Vice President, Corporate Communications & Public Relations
    Tel: +1-949-284-4506
    Email: media@evolus.com


    Primary Logo

Share on,